H. Lundbeck A/S (CPH:HLUN.B)
Denmark · Delayed Price · Currency is DKK 42.56
-0.08 (-0.19%)
Sep 18, 2026, 4:59 PM CET
H. Lundbeck Revenue
H. Lundbeck had revenue of 6.46B DKK in the quarter ending June 30, 2026, with 7.31% growth. This brings the company's revenue in the last twelve months to 25.96B, up 10.37% year-over-year. In the year 2025, H. Lundbeck had annual revenue of 24.63B with 11.93% growth.
Revenue (ttm)
25.96B
Revenue Growth
+10.37%
P/S Ratio
1.61
Revenue / Employee
5.19M
Employees
5,000
Market Cap
41.78B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 24.63B | 2.63B | 11.93% |
| Dec 31, 2024 | 22.00B | 2.09B | 10.51% |
| Dec 31, 2023 | 19.91B | 1.67B | 9.13% |
| Dec 31, 2022 | 18.25B | 1.95B | 11.95% |
| Dec 31, 2021 | 16.30B | -1.37B | -7.77% |
| Dec 31, 2020 | 17.67B | 636.00M | 3.73% |
| Dec 31, 2019 | 17.04B | -1.08B | -5.97% |
| Dec 31, 2018 | 18.12B | 883.00M | 5.12% |
| Dec 31, 2017 | 17.23B | 1.60B | 10.23% |
| Dec 31, 2016 | 15.63B | 1.04B | 7.13% |
| Dec 31, 2015 | 14.59B | 1.13B | 8.36% |
| Dec 31, 2014 | 13.47B | -1.79B | -11.73% |
| Dec 31, 2013 | 15.26B | 456.00M | 3.08% |
| Dec 31, 2012 | 14.80B | -1.21B | -7.53% |
| Dec 31, 2011 | 16.01B | 1.24B | 8.41% |
| Dec 31, 2010 | 14.77B | 1.02B | 7.41% |
| Dec 31, 2009 | 13.75B | 2.18B | 18.80% |
| Dec 31, 2008 | 11.57B | 587.10M | 5.34% |
| Dec 31, 2007 | 10.98B | 1.76B | 19.13% |
| Dec 31, 2006 | 9.22B | 151.20M | 1.67% |
| Dec 31, 2005 | 9.07B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 329.43B |
| Coloplast | 28.44B |
| Genmab | 27.03B |
| Demant | 24.63B |
| GN Store Nord | 16.46B |
| ALK-Abelló | 6.83B |
| Embla Medical | 6.44B |
| Bavarian Nordic | 6.34B |
H. Lundbeck News
- 3 days ago - Lundbeck Receives Marketing Authorization For Vyepti In Japan For The Prevention Of Migraine Attacks - Nasdaq
- 4 days ago - Lundbeck Completes DEEp SEA Randomization; Phase III Bexicaserin Trial In Dravet Syndrome Advances - Nasdaq
- 4 days ago - Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome - PRNewsWire
- 8 days ago - Lundbeck Secures FDA Orphan Drug Designation For Asedebart In Cushing's Syndrome - Nasdaq
- 8 days ago - The U.S. FDA grants orphan drug designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for treatment of endogenous Cushing's syndrome - PRNewsWire
- 26 days ago - European Commission Grants Orphan Designation For Lundbeck's Asedebart For Cushing's Syndrome - Nasdaq
- 4 weeks ago - H. Lundbeck Quarterly report: Q2 2026 - Filings
- 4 weeks ago - H. Lundbeck Slides: Q2 2026 - Filings